Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 786 across all filing types
Latest filing 2017-11-09 Regulatory Filings
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from Lipocine Inc. to the SEC withdrawing a previous request for acceleration of the effectiveness of a Registration Statement on Form S-3. It is correspondence related to regulatory filings and does not contain financial data, report content, or detailed financial statements. The document is short (1290 characters) and serves as a formal notice rather than a report or financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such correspondence and notices to the SEC.
2017-11-09 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from Lipocine Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It references a specific filing (Form S-3) and requests an administrative action (acceleration of effectiveness). The content is a formal correspondence related to a regulatory filing process, not the filing itself or a financial report. The document length is short (1037 characters), and it does not contain financial data or report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence with the SEC that do not fit other categories.
2017-11-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2017, by Lipocine Inc. The key content is an update to the company's corporate presentation used for investor meetings, which is attached as Exhibit 99.1. The document does not contain financial statements or detailed financial analysis but rather announces the filing of a presentation. The length is 2727 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, announcements of presentations or reports that are short and primarily notify about the filing of such materials should be classified as Regulatory Filings (RNS).
2017-11-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2017, by Lipocine Inc. It reports the issuance of a press release announcing financial and operational results for the three and nine months ended September 30, 2017. The document itself does not contain detailed financial statements or substantive financial data but references a press release as an exhibit. The length of the document is 2961 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of financial results rather than the results themselves. Therefore, the appropriate classification is Earnings Release (ER), as the document announces quarterly/periodical financial results highlights via a press release.
2017-11-08 English
10-Q
Interim / Quarterly Report Q3 2017
2017-11-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes references to clinical study presentations at a conference and attached exhibits with presentation materials. There are no financial statements or detailed financial data included. The document is short (3158 characters) and primarily announces upcoming presentations and provides exhibits related to those presentations. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain a full report or detailed financial results. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-10-25 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.